Video: New Topical Drug Delivery System, NeuroDirect™

Must Watch Video. Topical Application to Improve Delivery of FDA-Approved Drugs. https://youtu.be/2CGT7P9QEvo Can...

Topical PTSD Drug Poised for Human Trials.

In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid...
Zappy Zapolin, Lamar Odom, Roland Rick Perry

Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.

Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our...

Pivotal Clinical Trials: Frequently Asked Questions (Sofpromed).

What is a pivotal clinical trial? A pivotal clinical trial is a clinical study seeking...

Adding Cardiol Therapeutics (CRDL) $0.59 to Watch List.

Adding to 2023 Biotech Stock Review Watch List. We Think This One Has Legs. Starting Due Diligence...

Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?

After dropping 94% from post IPO high from $19.45, a loss exceeding $3 billion and change, ATAI is in the early stages of recovery (in...

The Ketamine Endgame. Silo Pharmaceutical (SILO).

James Kuo, M.D. the Vice President of R&D for Silo Pharma (SILO) will speak at the 3rd...

The Ketamine Cure (NY Times)

The once-taboo drug has been repurposed to treat depression and is even available for delivery. But how safe is it?

The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s Novel Topical Ketamine Delivery.

Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side Effects

Ardelyx (ARDX) Resubmits New Drug Application to FDA.

WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...

Latest article

Asia-Pacific: A Region of Stability Amidst Economic Uncertainty

Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...

A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...